Agreement with Japan's leading medical equipment provider broadens
availability of Masimo SET to the global clinical community
IRVINE, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI),
the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low
Perfusion pulse oximetry, and Nihon Kohden, one of the largest patient
monitoring companies in the world, jointly announce an expanded technology
licensing agreement that calls for the integration of Masimo SET into Nihon
Kohden bedside and patient monitoring products worldwide.
"Growing clinical preference for Masimo SET continues to drive pulse
oximetry technology selection for our customers," stated Kazuo Ogino, Chairman
and CEO of Nihon Kohden. "We began integrating Masimo SET into Nihon Kohden
products in the U.S. and Canada in 2006. The demand for Masimo technology
worldwide continues to grow and we want to provide our customers with their
preference of pulse oximetry technology. I believe the collaboration between
Masimo and Nihon Kohden will create a great opportunity for our customers who
look for an effective and reliable patient monitoring solution."
An important contributor in the advancement of modern medical treatment,
Nihon Kohden is responsible for the invention of pulse oximetry. Today, with
subsidiaries in the USA, Europe and Asia, and distributors in nearly every
country in the world, Nihon Kohden is Japan's leading manufacturer, developer
and distributor of medical electronic equipment, including: patient monitors,
defibrillators, ECGs, EEGs, EP/EMGs, and hematology analyzers.
Masimo Founder and CEO, Joe E. Kiani, stated, "We look forward to
continuing our partnership with Nihon Kohden to deliver advanced pulse
oximetry solutions to customers in every part of the world. The expansion of
our technology license broadens clinical access to 'gold standard' Masimo SET
pulse oximetry and reinforces Nihon Kohden's continued commitment to customer
satisfaction."
About Nihon Kohden Corporation
Nihon Kohden is Japan's leading manufacturer, developer and distributor of
patient monitors, defibrillators, ECGs, EEGs, EP/EMGs, hematology analyzers
and other medical electronic equipment, with subsidiaries in the United
States, Europe, and Asia, and distributors in nearly every country in the
world. Nihon Kohden is a publicly held company listed in the First Section of
the Tokyo Stock Exchange. In addition to designing medical equipment for
hospital and clinic use, Nihon Kohden actively contributes to the advance of
medical technology. For more information, visit the Company's web site at
http://www.nihonkohden.com.
About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care -- helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse
oximetry, known as Masimo SET, which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Masimo Rainbow SET Pulse CO-Oximetry continuously and noninvasively measures
total hemoglobin (SpHbTM), oxygen content (SpOCTM), carboxyhemoglobin
(SpCO(R)), methemoglobin (SpMet(R)), and PVITM, in addition to oxyhemoglobin
(SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection
and treatment of potentially life-threatening conditions. Founded in 1989,
Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications."
Additional information about Masimo and its products may be found at
http://www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of which are
beyond our control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a result
of various risk factors, including, but not limited to: risks related to our
assumption that this worldwide Masimo SET technology license agreement with
Nihon Kohden will serve to increase market acceptance and adoption of the
technology, and risk related to our assumption that this technology licensing
agreement will serve to substantially increase revenues, as well as other
factors discussed in the "Risk Factors" section of our Quarterly Report on
Form 10-Q for the fiscal quarter ended September 27, 2008, filed with the
Securities and Exchange Commission ("SEC") on October 29, 2008, which may be
obtained for free at the SEC's website at http://www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any obligation to
update, amend or clarify these forward-looking statements or the "Risk
Factors" contained in our Quarterly Report on Form 10-Q for the fiscal quarter
ended September 27, 2008, whether as a result of new information, future
events or otherwise, except as may be required under the applicable securities
laws.
Contact:
Dana Banks
Masimo Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9,
Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or
registered trademarks of Masimo Corporation.
SOURCE Masimo
-0- 11/18/2008
/CONTACT: Dana Banks of Masimo Corporation, +1-949-297-7348/
/Web site: http://www.masimo.com /
(MASI)
CO: Masimo; Nihon Kohden Corporation
ST: California, Japan
IN: HEA BIO MTC
SU: LIC
HM-JP
-- LATU059 --
9862 11/18/2008 07:00 EST http://www.prnewswire.com